Core Insights - Coloplast reported Q1 organic growth of 6% and EBIT growth in constant currencies of 3%, with a return on invested capital of 15% [1][9] Financial Performance - Reported revenue in DKK grew 0%, impacted by a 4 percentage points negative effect from currencies [1] - EBIT was DKK 1,850 million, with a reported EBIT margin of 26%, down from 27% last year [4] - Free cash flow-to-sales ratio improved to 26% from 24% last year [9] Business Area Performance - Ostomy Care experienced a soft start with 4% growth, affected by negative growth in China and a high baseline in the US [2] - Continence Care grew by 7%, driven by strong contributions from Luja™ [2] - Voice & Respiratory Care saw an 8% increase, supported by growth in Laryngectomy [2] - Wound & Tissue Repair had a mixed performance, with Kerecis showing 10% organic growth but facing challenges due to Medicare reimbursement changes [2][3] - Advanced Wound Dressings declined by 3% due to product returns in China, impacting revenue by approximately DKK 25 million [3] - Interventional Urology showed strong growth, particularly in the US Men's Health business [3] Future Guidance - FY 2025/26 guidance remains unchanged, targeting around 7% organic revenue growth and EBIT growth in constant currencies [6] - Kerecis is now expected to deliver around 10% growth, down from a previous estimate of 25% due to sales disruptions [7] - Reported growth in DKK is anticipated at around 4%, with a negative currency impact of approximately 3 percentage points [7] Strategic Developments - Coloplast US plans to acquire Uromedica, a company specializing in stress urinary incontinence treatment, expected to close in February 2026 [5]

Core Insights - Coloplast reported a Q4 organic growth of 7% and an EBIT margin of 28%, with reported revenue in DKK remaining flat due to currency impacts and the divestment of the Skin Care segment [1][6] Business Area Performance - **Ostomy Care**: Achieved 7% organic growth, driven by product launches, particularly in Europe and Emerging Markets, while sales in China declined due to negative consumer sentiment and competitive pressures [2] - **Continence Care**: Growth of 9% was supported by strong sales of the Luja™ product for both male and female users [2] - **Voice & Respiratory Care**: Experienced 9% growth, attributed to strong performance in Laryngectomy and Tracheostomy segments [2] - **Wound & Tissue Repair**: Kerecis grew by 20% with a 14% EBIT margin before PPA amortization; however, Advanced Wound Dressings saw a decline of 6% due to a product return in China, impacting revenue by approximately DKK 60 million [3] - **Interventional Urology**: Growth was driven by the US Men's Health business, partially offset by a product recall in Kidney & Bladder Health, which negatively impacted revenue by around DKK 15 million in Q4 [4] Financial Performance - EBIT for the year was DKK 7,670 million, reflecting a 5% increase from the previous year, with an EBIT margin of 28%, up from 27% [11] - Adjusted net profit before special items was DKK 5,148 million, a DKK 123 million increase year-over-year, with adjusted diluted EPS before special items rising by 2% to DKK 22.84 [11] - The Board of Directors recommended a year-end dividend of DKK 18.00 per share, totaling DKK 23.00 for the year, compared to DKK 22.00 last year [7] Future Guidance - For FY 2025/26, the company anticipates around 7% organic revenue growth and EBIT growth in constant currencies, with reported growth in DKK expected at 4-5% [8] - The guidance assumes continued strong performance in Chronic Care and improved momentum in Acute Care, with a negative impact from currencies and the Skin Care divestment [8] - EBIT growth in constant currencies is expected to be supported by stable inflation levels and new investments related to the Impact4 strategy [9]